[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Immunotherapy Drugs Market Size, Share & Trends Analysis Report By Drug Type (Monoclonal Antibodies, Immunomodulators), By Indication (Infectious Diseases, Cancer), By Region, And Segment Forecasts, 2025 - 2030

December 2024 | 100 pages | ID: IC264FA83FB4EN
Grand View Research, Inc.

US$ 5,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 3 Business Days

Immunotherapy Drugs Market Growth & Trends

The global immunotherapy drugs market size is estimated treach USD 577.2 billion by 2030, expanding at a CAGR of 13.6% from 2025 t2030, according ta new report by Grand View Research, Inc. The key factors contributing tthe lucrative growth of the industry include increased awareness about chronic diseases including cancer, autoimmune diseases, inflammatory diseases, and infectious diseases, coupled with supportive government policies for drug approval. The rising adoption of targeted therapies for chronic disease treatment is expected tincrease inclination toward immunotherapy drugs, thereby driving the industry during the forecast period.

For instance, in May 2022, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab) received U.S. approval for treating HER2-positive breast cancer. Other targeted immunotherapy drugs include Kadcyla (trastuzumab emtansine) and Tecentriq (atezolizumab). In June 2022, F. Hoffmann-La Roche Ltd. received EU approval for Tecentriq as an adjuvant treatment for NSCLC. In addition, developing healthcare infrastructure in low- and middle-income countries coupled with increased research & development by key players is anticipated tcontribute tthe industry growth. For instance, in December 2021, Novartis AG collaborated with BeiGene, Ltd. for ociperlimab (BGB-A1217), therefore expanding its R&D activities in immune-oncology.

In August 2021, Pfizer, Inc. shared positive results from phase 2b/3 clinical trial of ritlecitinib for treating alopecia areata. Moreover, the rise in the incidence of cancer cases worldwide is expected tdrive the demand for immunotherapy drugs. As per Globocan reports, an estimated 19.3 million new oncology cases were diagnosed in 2020. Moreover, according tthe European Society of Medical Oncology, cancer incidence in Europe is anticipated trise by 21% between 2020 and 2040. Thus, approvals of various immunotherapy drugs for cancer treatment are predicted tincrease industry growth.

Immunotherapy Drugs Market Report Highlights
    • The monoclonal antibodies segment accounted for the largest share of 76.2% in 2024. This growth is due tincreased research and development in therapeutic monoclonal antibodies and supportive government initiatives.
    • The growth can be attributed tthe high demand for biologics treatment for various chronic diseases, such as cardiovascular, respiratory, and autoimmune diseases
    • The cancer segment dominated the market, accounting for 91.4% of the revenue in 2024 due tthe increased incidence of cancer globally and improved healthcare infrastructure in low- and middle-income countries
  • The North America immunotherapy market dominated the global market, with a revenue share of 49.9% in 2024
    • This is due tthe increased adoption of immunotherapy, supportive reimbursement policies, and increased healthcare expenditure in the region
CHAPTER 1. METHODOLOGY AND SCOPE

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
  1.3.1. Information Procurement
  1.3.2. Information or Data Analysis
  1.3.3. Market Formulation & Data Visualization
  1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
  1.4.1. List of Data Sources

CHAPTER 2. EXECUTIVE SUMMARY

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

CHAPTER 3. IMMUNOTHERAPY DRUGS MARKET VARIABLES, TRENDS, & SCOPE

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
  3.3.1. Market Drivers Analysis
  3.3.2. Market Restraints Analysis
3.4. Immunotherapy Drugs Market Analysis Tools
  3.4.1. Porter’s Analysis
    3.4.1.1. Bargaining power of the suppliers
    3.4.1.2. Bargaining power of the buyers
    3.4.1.3. Threats of substitution
    3.4.1.4. Threats from new entrants
    3.4.1.5. Competitive rivalry
  3.4.2. PESTEL Analysis
    3.4.2.1. Political landscape
    3.4.2.2. Economic and Social landscape.
    3.4.2.3. Technological landscape
    3.4.2.4. Environmental landscape
    3.4.2.5. Legal landscape

CHAPTER 4. IMMUNOTHERAPY DRUGS MARKET: DRUG TYPE ESTIMATES & TREND ANALYSIS

4.1. Drug Type Market Share, 2024 & 2030
4.2. Drug Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
4.4. Monoclonal Antibodies
  4.4.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Immunomodulator
  4.5.1. Immunomodulator Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Vaccine
  4.6.1. Vaccine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

CHAPTER 5. IMMUNOTHERAPY DRUGS MARKET: INDICATION ESTIMATES & TREND ANALYSIS

5.1. Indication Market Share, 2024 & 2030
5.2. Indication Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
5.4. Cancer
  5.4.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Autoimmune Diseases
  5.5.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Infectious Diseases
  5.6.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Others
  5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

CHAPTER 6. IMMUNOTHERAPY DRUGS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
6.4. North America
  6.4.1. North America Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.4.2. U.S.
    6.4.2.1. Key Country Dynamics
    6.4.2.2. Regulatory Framework
    6.4.2.3. Competitive Insights
    6.4.2.4. U.S. Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.4.3. Canada
    6.4.3.1. Key Country Dynamics
    6.4.3.2. Regulatory Framework
    6.4.3.3. Competitive Insights
    6.4.3.4. Canada Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.4.4. Mexico
    6.4.4.1. Key Country Dynamics
    6.4.4.2. Regulatory Framework
    6.4.4.3. Competitive Insights
    6.4.4.4. Mexico Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Europe
  6.5.1. Europe Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.5.2. UK
    6.5.2.1. Key Country Dynamics
    6.5.2.2. Regulatory Framework
    6.5.2.3. Competitive Insights
    6.5.2.4. UK Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.5.3. Germany
    6.5.3.1. Key Country Dynamics
    6.5.3.2. Regulatory Framework
    6.5.3.3. Competitive Insights
    6.5.3.4. Germany Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.5.4. France
    6.5.4.1. Key Country Dynamics
    6.5.4.2. Regulatory Framework
    6.5.4.3. Competitive Insights
    6.5.4.4. France Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.5.5. Italy
    6.5.5.1. Key Country Dynamics
    6.5.5.2. Regulatory Framework
    6.5.5.3. Competitive Insights
    6.5.5.4. Italy Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.5.6. Spain
    6.5.6.1. Key Country Dynamics
    6.5.6.2. Regulatory Framework
    6.5.6.3. Competitive Insights
    6.5.6.4. Spain Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.5.7. Denmark
    6.5.7.1. Key Country Dynamics
    6.5.7.2. Regulatory Framework
    6.5.7.3. Competitive Insights
    6.5.7.4. Denmark Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.5.8. Sweden
    6.5.8.1. Key Country Dynamics
    6.5.8.2. Regulatory Framework
    6.5.8.3. Competitive Insights
    6.5.8.4. Sweden Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.5.9. Norway
    6.5.9.1. Key Country Dynamics
    6.5.9.2. Regulatory Framework
    6.5.9.3. Competitive Insights
    6.5.9.4. Norway Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Asia Pacific
  6.6.1. Asia Pacific Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.6.2. Japan
    6.6.2.1. Key Country Dynamics
    6.6.2.2. Regulatory Framework
    6.6.2.3. Competitive Insights
    6.6.2.4. Japan Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.6.3. China
    6.6.3.1. Key Country Dynamics
    6.6.3.2. Regulatory Framework
    6.6.3.3. Competitive Insights
    6.6.3.4. China Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.6.4. India
    6.6.4.1. Key Country Dynamics
    6.6.4.2. Regulatory Framework
    6.6.4.3. Competitive Insights
    6.6.4.4. India Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.6.5. Thailand
    6.6.5.1. Key Country Dynamics
    6.6.5.2. Regulatory Framework
    6.6.5.3. Competitive Insights
    6.6.5.4. Thailand Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.6.6. South Korea
    6.6.6.1. Key Country Dynamics
    6.6.6.2. Regulatory Framework
    6.6.6.3. Competitive Insights
    6.6.6.4. South Korea Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.6.7. Australia
    6.6.7.1. Key Country Dynamics
    6.6.7.2. Regulatory Framework
    6.6.7.3. Competitive Insights
    6.6.7.4. Australia Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Latin America
  6.7.1. Latin America Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.7.2. Brazil
    6.7.2.1. Key Country Dynamics
    6.7.2.2. Regulatory Framework
    6.7.2.3. Competitive Insights
    6.7.2.4. Brazil Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.7.3. Argentina
    6.7.3.1. Key Country Dynamics
    6.7.3.2. Regulatory Framework
    6.7.3.3. Competitive Insights
    6.7.3.4. Argentina Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Middle East and Africa
  6.8.1. Middle East and Africa Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.8.2. South Africa
    6.8.2.1. Key Country Dynamics
    6.8.2.2. Regulatory Framework
    6.8.2.3. Competitive Insights
    6.8.2.4. South Africa Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.8.3. Saudi Arabia
    6.8.3.1. Key Country Dynamics
    6.8.3.2. Regulatory Framework
    6.8.3.3. Competitive Insights
    6.8.3.4. Saudi Arabia Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.8.4. UAE
    6.8.4.1. Key Country Dynamics
    6.8.4.2. Regulatory Framework
    6.8.4.3. Competitive Insights
    6.8.4.4. UAE Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  6.8.5. Kuwait
    6.8.5.1. Key Country Dynamics
    6.8.5.2. Regulatory Framework
    6.8.5.3. Competitive Insights
    6.8.5.4. Kuwait Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

CHAPTER 7. COMPETITIVE LANDSCAPE

7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
  7.5.1. Amgen Inc.
    7.5.1.1. Participant’s Overview
    7.5.1.2. Financial Performance
    7.5.1.3. Product Benchmarking
    7.5.1.4. Recent Developments/ Strategic Initiatives
  7.5.2. Novartis AG
    7.5.2.1. Participant’s Overview
    7.5.2.2. Financial Performance
    7.5.2.3. Product Benchmarking
    7.5.2.4. Recent Developments/ Strategic Initiatives
  7.5.3. AbbVie Inc.
    7.5.3.1. Participant’s Overview
    7.5.3.2. Financial Performance
    7.5.3.3. Product Benchmarking
    7.5.3.4. Recent Developments/ Strategic Initiatives
  7.5.4. Pfizer Inc.
    7.5.4.1. Participant’s Overview
    7.5.4.2. Financial Performance
    7.5.4.3. Product Benchmarking
    7.5.4.4. Recent Developments/ Strategic Initiatives
  7.5.5. F. Hoffmann-La Roche Ltd
    7.5.5.1. Participant’s Overview
    7.5.5.2. Financial Performance
    7.5.5.3. Product Benchmarking
    7.5.5.4. Recent Developments/ Strategic Initiatives
  7.5.6. Johnson & Johnson Services, Inc.
    7.5.6.1. Participant’s Overview
    7.5.6.2. Financial Performance
    7.5.6.3. Product Benchmarking
    7.5.6.4. Recent Developments/ Strategic Initiatives
  7.5.7. AstraZeneca
    7.5.7.1. Participant’s Overview
    7.5.7.2. Financial Performance
    7.5.7.3. Product Benchmarking
    7.5.7.4. Recent Developments/ Strategic Initiatives
  7.5.8. GSK plc.
    7.5.8.1. Participant’s Overview
    7.5.8.2. Financial Performance
    7.5.8.3. Product Benchmarking
    7.5.8.4. Recent Developments/ Strategic Initiatives
  7.5.9. Sanofi
    7.5.9.1. Participant’s Overview
    7.5.9.2. Financial Performance
    7.5.9.3. Product Benchmarking
    7.5.9.4. Recent Developments/ Strategic Initiatives
  7.5.10. Bayer AG
    7.5.10.1. Participant’s Overview
    7.5.10.2. Financial Performance
    7.5.10.3. Product Benchmarking
    7.5.10.4. Recent Developments/ Strategic Initiatives


More Publications